Suggested remit: To appraise the clinical and cost effectiveness of talazoparib within its marketing authorisation for treating BRCA 1 or 2 mutated advanced breast cancer.
Status In progress
Process STA 2018
ID number 1342

Provisional Schedule

Expected publication 18 November 2020

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
18 September 2019 As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy. This appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that this drug will consequently not be eligible to receive interim CDF funding from the date of marketing authorisation. It is anticipated that the appraisal will begin in late January 2020 when we will write to you about how you can get involved.
05 July 2018 - 02 August 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
13 February 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance